Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreement with Celltrion Healthcare Co., Ltd, a global biopharmaceutical company, for Vegzelma (CT-P16, bevacizumab).
Under the terms of the agreement, Celltrion Healthcare will be responsible for the development, manufacturing and supply of Vegzelma and Hikma will be responsible for the commercialisation of the product in all its MENA markets, providing better access to a much needed oncology product.
Vegzelma is a biosimilar to Avastin (bevacizumab) and is a US FDA and EMA approved anti-cancer monoclonal antibody treatment. The new agreement builds on Hikma
